High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia

American Journal of Medicine

Volumn 104, Issue 6, 1998, Pages 517-525

  Meigs, James B ^c   Barry, Michael J ^d   Giovannucci, Edward ^a   Rimm, Eric B ^a   Stampfer, Meir J ^a   Kawachi, Ichiro ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Depts of Health and Social Behavior   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; SCREENING TEST; URETHRA DISEASE;

AGED; AGED, 80 AND OVER; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; ODDS RATIO; PREVALENCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK FACTORS; UNITED STATES;

EID: 0032104338     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00113-2     Document Type: Article

References (36)

1. 1. Guess H. Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev. 1992;14:131-153.
2. 2. Parker SL, long T, Bolden S, Wingo PA. Cancer Statistics, 1996. CA Cancer J Clin. 1996;46:5-27.
3. 3. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med. 1993;118:793-803.
4. 4. Woolf SH. Screening for prostate cancer with prostate-specific antigen. NEJM. 1995;333:1401-1405.
5. 5. Mettlin C, Jones G, Averette H, et al. Defining and updating the American Cancer Society guidlines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin. 1993;43:42-47.
6. 6. Potosky AL, Miller BA, Albertson PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548-552.
7. 7. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA. 1995;274:1445-1449.
8. 8. Oesterling JE. Prostate specific antigen. A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145:907-923.
9. 9. Monda JM, Barry MJ, Oesterling JE. Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia. J Urol. 1994;151:1291-1295.
10. 10. Sershon PD, Barry MJ, Oesterling JE. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer. Euro Urol. 1994;25:281-287.
11. 11. Gillatt D, Reynard JM. What is the "normal range" for prostate-specific antigen? Use of a receiver operating characteristic curve to evaluate a serum marker. Br J Urol. 1995;75:341-346.
12. 12. Meigs JB, Barry MJ, Oesterling JE, Jacobsen SJ. Interpreting results of prostate-specific antigen testing for early detection of prostate cancer. J Gen Intern Med. 1996;11:505-512.
13. 13. Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer. 1991;67: 2949-2958.
14. 14. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283-1290.
15. 15. Hiatt RA, Armstrong MA, Klatsky AL, Sidney S. Alcohol consumption, smoking, and other risk factors and prostate cancer in a large health plan cohort in California (United States). Cancer Cause Control. 1994;5:66-72.
16. 16. Giovannucci E, Rimm EB, Chute CG, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994;140:989-1002.
17. 17. Barry MJ Jr, Fowler FJ, O'Leary MP, et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol 1992;148:1549-1557.
18. 18. Giovannucci E, Ascherio A, Rimm EB, et al. A prospective cohort study of vasectomy and prostate cancer in U.S. men. JAMA. 1992; 269:873-877.
19. 19. Meigs JB, Barry MJ. The natural history of benign prostatic hyperplasia. In: Kirby RS, McConnell JD, Fitzpatrick JM, et al, eds. Textbook of Benign Prostatic Hyperplasia. Oxford: Isis Medical Media; 1996:125-135.
20. 20. Barry MJ, Fowler FJ, O'Leary MP, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care. 1995;33(suppl):AS145-AS155.
21. 21. Barry MJ, Willerford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measurements in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol. 1995;154:1770-1774.
22. 22. Rothman KJ. Modern Epidemiology. Boston, Mass: Little, Brown, and Co; 1986.
23. 23. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: Wiley-Interscience; 1989.
24. 24. SAS/STAT User's Guide. Version 6, 4th ed. Cary, NC: SAS Institute, Inc; 1989.
25. 25. Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1996.
26. 26. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. Baltimore, Md: William and Wilkins; 1989.
27. 27. American Urological Association Executive Committee Report, 1992. Baltimore, Md: American Urological Association; 1992.
28. 28. Albertsen PC, Fryback DG, Storer BE, et al. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995;274:626-631.
29. 29. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy: time trends, geographic variation, and outcomes. JAMA. 1993;269:2633-2636.
30. 30. Fleming C, Wasson JH, Albertsen PC, et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA. 1993;269:2650-2658.
31. 31. Johansson J-E, Holmberg L, Johansson S, et al. Fifteen-year survival in prostate cancer: a prospective, population-based study in Sweden. JAMA. 1997;277:467-471.
32. 32. Barry MJ, Fleming C, Coley CM, et al. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: estimating the risks and benefits of an early detection program. Urology. 1995;46:445-461.
33. 33. Fowler FJ, Bin L, McNaughton Collins M, et al. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Am J Med. 1998;104:526-532.
34. 34. Gohogan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal, and ovarian cancer screening trial of the National Cancer Institute. J Urol. 1994;152: 1905-1909.
35. 35. Flood AB, Wennberg JE, Nease RF, et al. The importance of patient preference in the decision to screen for prostate cancer. J Gen Intern Med. 1996;11:342-349.
36. 36. Wolf AMD, Nasser JF, Wolf AM, Schorling JB. The impact of informed consent on patient interest in prostate-specific antigen screening. Arch Intern Med. 1996;156:1333-1336.